Literature DB >> 28267526

High intensity focused ultrasound treatment of adenomyosis: The relationship between the features of magnetic resonance imaging on T2 weighted images and the therapeutic efficacy.

Chunmei Gong1, Raymond Setzen2, Zhongqiong Liu1, Yunchang Liu1, Bin Xie3, Aixingzi Aili4, Lian Zhang5.   

Abstract

OBJECTIVES: To investigate the relationship between the features of magnetic resonance imaging (MRI) on T2 weighted images (T2WI) and the therapeutic efficacy of high intensity focused ultrasound (HIFU) on adenomyosis.
MATERIALS AND METHODS: From January 2011 to November 2015, four hundred and twenty-eight patients with symptomatic adenomyosis were treated with HIFU. Based on the signal intensity and the number of hyperintense foci in the adenomyotic lesions on T2WI, the patients were classified into groups. The day after HIFU ablation patients underwent contrast-enhanced MRI and a comparison was made of non-perfused volume (NPV) ratio, energy efficiency factor (EEF), treatment time, sonication time, and adverse effects.
RESULTS: No significant difference in terms of HIFU treatment settings and results was observed between the group of patients with hypointense adenomyotic lesions and the group with isointense adenomyotic lesions (P>0.05). However, the sonication time and EEF were significantly higher in the group with multiple hyperintense foci compared to the group with few hyperintense foci. The NPV ratio achieved in the lesions with multiple hyperintenese foci was significantly lower than that in the lesions with few hyperintense foci (P<0.05). No significant difference was observed in the rate of adverse effects between the two groups.
CONCLUSIONS: Based on our results, the response of the adenomyotic lesions to HIFU treatment is not related to the signal intensity of adenomyotic lesions on T2WI. However, the number of the high signal intensity foci in the adenomyotic lesions on T2WI can be considered as a predictive factor to help select patients for HIFU treatment.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Ablative efficiency; Adenomyosis; High intensity focused ultrasound (HIFU); Magnetic resonance imaging (MRI); Signal characteristics

Mesh:

Year:  2017        PMID: 28267526     DOI: 10.1016/j.ejrad.2017.02.001

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  5 in total

1.  [Stratified treatment and management of adenomyosis].

Authors:  Xinmei Zhang; Ping Xu
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2019-04-25

2.  Ultrasound-guided high-intensity focused ultrasound in the treatment of uterine fibroids.

Authors:  Hong-Jie Fan; Chao Zhang; Hong-Tao Lei; Jiang-Ping Cun; Wei Zhao; Jian-Qiang Huang; Yue Zhai
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.817

3.  Magnetic Resonance-Guided High-Intensity Focused Ultrasound Ablation of Uterine Fibroids-Efficiency Assessment with the Use of Dynamic Contrast-Enhanced Magnetic Resonance Imaging and the Potential Role of the Administration of Uterotonic Drugs.

Authors:  Tomasz Łoziński; Michał Ciebiera; Elżbieta Łuczyńska; Justyna Filipowska; Artur Czekierdowski
Journal:  Diagnostics (Basel)       Date:  2021-04-16

4.  Multidisciplinary management to optimize outcome of ultrasound-guided high-intensity focused ultrasound (HIFU) in patients with uterine fibroids.

Authors:  Florian Recker; Marcus Thudium; Rupert Conrad; Milka Marinova; Holger Strunk; Tolga Tonguc; Sara Dohmen; Guido Luechters; Birgit Bette; Simone Welz; Babak Salam; Kai Wilhelm; Eva K Egger; Ullrich Wüllner; Ulrike Attenberger; Alexander Mustea
Journal:  Sci Rep       Date:  2021-11-23       Impact factor: 4.379

5.  Prediction of Clinical Outcome for High-Intensity Focused Ultrasound Ablation of Uterine Leiomyomas Using Multiparametric MRI Radiomics-Based Machine Leaning Model.

Authors:  Yineng Zheng; Liping Chen; Mengqi Liu; Jiahui Wu; Renqiang Yu; Fajin Lv
Journal:  Front Oncol       Date:  2021-09-10       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.